Our Small Molecule division is focused on leveraging its technologies and expertise to address solubility challenges and support drug development programs through commercialization. Download our e-book to learn about the importance of patient-centric formulations. Discover how evaluating formulation approaches ensures the best option for the product, considering the target product profile, patient population and properties of the API.

In this e-book, you will find:

  • The advantages of multiparticulate formulations, especially for pediatric patients
  • Methods for improving the bioavailability of poorly soluble APIs 
  • Information on how the MSAT (Manufacturing, Science, and Technology) team supports late-stage process development and scale-up, commercial process validation, and process lifecycle management
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.
Latest briefing from the Knowledge Center